Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this study were:
1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV
infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days
of treatment.
2. To compare the exposure to ganciclovir, at steady state, after oral valganciclovir with
respect to ganciclovir given intravenously (i.v.).
3. Evaluate the security of this treatment with valganciclovir.